secwatch.observer — SEC 8-K summary
======================================

Issuer:     REGENERON PHARMACEUTICALS, INC. (REGN)
CIK:        0000872589
Form:       8-K
Filed at:   2023-08-03T23:59:59+00:00
Accession:  0001804220-23-000021
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Regeneron Q2 revenues up 11% to $3.16B; EPS $8.50 GAAP/$10.24 non-GAAP
----------------------------------------------------------------------

- Q2 2023 total revenues $3.158B (+11% YoY); GAAP diluted EPS $8.50 (up 14%); non-GAAP diluted EPS $10.24 (up 5%).
- Dupixent global net sales (Sanofi) rose 33% to $2.79B; EYLEA US net sales fell 7% to $1.50B on lower pricing/competition.
- FDA issued CRL for aflibercept 8 mg due to contract manufacturer issues; expects FDA action on BLA in Q3 2023.
- Repurchased $723M in shares during Q2; $2.3B remained under buyback program as of June 30, 2023.
- Updated 2023 guidance: GAAP R&D $4.315-4.455B; non-GAAP R&D $3.825-3.925B; SG&A and gross margin ranges unchanged.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/872589/000180422023000021/0001804220-23-000021-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/872589/000180422023000021/regn-20230803.htm
  HTML page:      https://secwatch.observer/filing/0001804220-23-000021

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer